Toxoplasma-gondii-Infektion in der Schwangerschaft – Empfehlungen der Arbeitsgemeinschaft Geburtshilfe und Pränatalmedizin (AGG – Sektion Maternale Erkrankungen)

Zusammenfassung

Ziel Diese Empfehlungen der AGG (Arbeitsgemeinschaft für Geburtshilfe und Pränatalmedizin, Sektion maternale Erkrankungen) haben das Ziel der Verbesserung der Diagnostik und des Managements von Toxoplasma-gondii-Infektionen in der Schwangerschaft.

Methoden Basierend auf der aktuellen Literatur entwickelten die Mitglieder der Task Force die vorliegenden Empfehlungen und Stellungnahmen. Diese Empfehlungen wurden nach einem Konsens der Mitglieder der Arbeitsgruppe verabschiedet.

Empfehlungen Das folgende Manuskript beschäftigt sich mit der Epidemiologie und Pathophysiologie von Toxoplasma-gondii-Infektionen in der Schwangerschaft und enthält Empfehlungen zu maternaler und fetaler Diagnostik, Transmissionsprophylaxe, Therapie, Prävention, Screening und peripartalem Management.

Schlüsselwörter

Schwangerschaft - Toxoplasmose - Diagnostik - Transmissionsprophylaxe - Therapie

Publication History

Received: 14 June 2023

Accepted after revision: 18 July 2023

Article published online:
18 September 2023

• References/Literatur

• 1 Robert Koch-Institut. RKI-Ratgeber Toxoplasmose. Epidemiol Bull 2018; 42: 451-460
• 2 Wilking H, Thamm M, Stark K. et al. Prevalence, incidence estimations, and risk factors of Toxoplasma gondii infection in Germany: a representative, cross-sectional, serological study. Sci Rep 2016; 6: 22551
• 3 Pleyer U, Groß U, Schlüter D. et al. Toxoplasmosis in Germany: Epidemiology, Diagnosis, Risk Factors, and Treatment. Dtsch Arztebl Int 2019; 116: 435-444
• 4 Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet 2004; 363: 1965-1976
• 5 Beringer T. [Is diagnosis of toxoplasmosis within the scope of prenatal care meaningful?]. Geburtshilfe Frauenheilkd 1992; 52: 740-741
• 6 Krings A, Jacob J, Seeber F. et al. Estimates of Toxoplasmosis Incidence Based on Healthcare Claims Data, Germany, 2011–2016. Emerg Infect Dis 2021; 27: 2097-2106
• 7 Prusa A-R, Kasper DC, Pollak A. et al. The Austrian Toxoplasmosis Register, 1992–2008. Clin Infect Dis 2015; 60: e4-e10
• 8 Paquet C, Yudin MH. No. 285-Toxoplasmosis in Pregnancy: Prevention, Screening, and Treatment. J Obstet Gynaecol Can 2018; 40: e687-e693
• 9 Leruez-Ville M, Benoist G, Ville Y. Fetal Infections: Clinical Management. In: Kilby MD, Johnson A, Oepkes D, eds. Fetal Therapy. Cambridge University Press; 2019: 224-247
• 10 Hotop A, Hlobil H, Gross U. Efficacy of rapid treatment initiation following primary Toxoplasma gondii infection during pregnancy. Clin Infect Dis 2012; 54: 1545-1552
• 11 Dubey JP, Murata FHA, Cerqueira-Cézar CK. et al. Congenital toxoplasmosis in humans: an update of worldwide rate of congenital infections. Parasitology 2021; 148: 1406-1416
• 12 Picone O, Fuchs F, Benoist G. et al. Toxoplasmosis screening during pregnancy in France: Opinion of an expert panel for the CNGOF. J Gynecol Obstet Hum Reprod 2020; 49: 101814
• 13 Codaccioni C, Picone O, Lambert V. et al. Ultrasound features of fetal toxoplasmosis: A contemporary multicenter survey in 88 fetuses. Prenat Diagn 2020; 40: 1741-1752
• 14 Kieffer F, Wallon M, Garcia P. et al. Risk factors for retinochoroiditis during the first 2 years of life in infants with treated congenital toxoplasmosis. Pediatr Infect Dis J 2008; 27: 27-32
• 15 SYROCOT (Systematic Review on Congenital Toxoplasmosis) study group. Thiébaut R, Leproust S. et al. Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patientsʼ data. Lancet 2007; 369: 115-122
• 16 Berrébi A, Assouline C, Bessières M-H. et al. Long-term outcome of children with congenital toxoplasmosis. Am J Obstet Gynecol 2010; 203: 552.e1-552.e6
• 17 Dunn D, Wallon M, Peyron F. et al. Mother-to-child transmission of toxoplasmosis: risk estimates for clinical counselling. Lancet 1999; 353: 1829-1833
• 18 Wallon M, Peyron F, Cornu C. et al. Congenital toxoplasma infection: monthly prenatal screening decreases transmission rate and improves clinical outcome at age 3 years. Clin Infect Dis 2013; 56: 1223-1231
• 19 Gilbert RE, Freeman K, Lago EG. et al. Ocular sequelae of congenital toxoplasmosis in Brazil compared with Europe. PLoS Negl Trop Dis 2008; 2: e277
• 20 Tan HK, Schmidt D, Stanford M. et al. Risk of visual impairment in children with congenital toxoplasmic retinochoroiditis. Am J Ophthalmol 2007; 144: 648-653
• 21 Wallon M, Kodjikian L, Binquet C. et al. Long-term ocular prognosis in 327 children with congenital toxoplasmosis. Pediatrics 2004; 113: 1567-1572
• 22 Peyron F, Garweg JG, Wallon M. et al. Long-term impact of treated congenital toxoplasmosis on quality of life and visual performance. Pediatr Infect Dis J 2011; 30: 597-600
• 23 Roizen N, Kasza K, Karrison T. et al. Impact of visual impairment on measures of cognitive function for children with congenital toxoplasmosis: implications for compensatory intervention strategies. Pediatrics 2006; 118: e379-e390
• 24 Eichenwald HF. A study of congenital toxoplasmosis, with particular emphasis on clinical manifestations, sequelae and therapy. In: Siim JC. ed. Human toxoplasmosis. Copenhagen: Munksgaard; 1960: 41-49
• 25 Hutson SL, Wheeler KM, McLone D. et al. Patterns of Hydrocephalus Caused by Congenital Toxoplasma gondii Infection Associate With Parasite Genetics. Clin Infect Dis 2015; 61: 1831-1834
• 26 McLone D, Frim D, Penn R. et al. Outcomes of hydrocephalus secondary to congenital toxoplasmosis. J Neurosurg Pediatr 2019;
• 27 Anand R, Jones CW, Ricks JH. et al. Acute primary toxoplasmosis in travelers returning from endemic countries. J Travel Med 2012; 19: 57-60
• 28 Rudzinski M, Khoury M, Couto C. et al. Reactivation of Ocular Toxoplasmosis in Non-Hispanic Persons, Misiones Province, Argentina. Emerg Infect Dis 2016; 22: 912-913
• 29 Montoya JG, Remington JS. Management of Toxoplasma gondii infection during pregnancy. Clin Infect Dis 2008; 47: 554-566
• 30 Fricker-Hidalgo H, Cimon B, Chemla C. et al. Toxoplasma seroconversion with negative or transient immunoglobulin M in pregnant women: myth or reality? A French multicenter retrospective study. J Clin Microbiol 2013; 51: 2103-2111
• 31 Elbez-Rubinstein A, Ajzenberg D, Dardé M-L. et al. Congenital toxoplasmosis and reinfection during pregnancy: case report, strain characterization, experimental model of reinfection, and review. J Infect Dis 2009; 199: 280-285
• 32 Low incidence of congenital toxoplasmosis in children born to women infected with human immunodeficiency virus. European Collaborative Study and Research Network on Congenital Toxoplasmosis. Eur J Obstet Gynecol Reprod Biol 1996; 68: 93-96
• 33 Liesenfeld O, Montoya JG, Tathineni NJ. et al. Confirmatory serologic testing for acute toxoplasmosis and rate of induced abortions among women reported to have positive Toxoplasma immunoglobulin M antibody titers. Am J Obstet Gynecol 2001; 184: 140-145
• 34 Maldonado YA, Read JS. COMMITTEE ON INFECTIOUS DISEASES. Diagnosis, Treatment, and Prevention of Congenital Toxoplasmosis in the United States. Pediatrics 2017; 139: e20163860
• 35 Peyron F, Lʼollivier C, Mandelbrot L. et al. Maternal and Congenital Toxoplasmosis: Diagnosis and Treatment Recommendations of a French Multidisciplinary Working Group. Pathogens 2019; 8: 24
• 36 Khalil A, Sotiriadis A, Chaoui R. et al. ISUOG Practice Guidelines: role of ultrasound in congenital infection. Ultrasound Obstet Gynecol 2020; 56: 128-151
• 37 de Oliveira Azevedo CT, do Brasil PEAA, Guida L. et al. Performance of Polymerase Chain Reaction Analysis of the Amniotic Fluid of Pregnant Women for Diagnosis of Congenital Toxoplasmosis: A Systematic Review and Meta-Analysis. PloS One 2016; 11: e0149938
• 38 Sterkers Y, Pratlong F, Albaba S. et al. Novel Interpretation of Molecular Diagnosis of Congenital Toxoplasmosis According to Gestational Age at the Time of Maternal Infection. J Clin Microbiol 2012; 50: 3944-3951
• 39 Wallon M, Franck J, Thulliez P. et al. Accuracy of real-time polymerase chain reaction for Toxoplasma gondii in amniotic fluid. Obstet Gynecol 2010; 115: 727-733
• 40 Rabilloud M, Wallon M, Peyron F. In utero and at birth diagnosis of congenital toxoplasmosis: use of likelihood ratios for clinical management. Pediatr Infect Dis J 2010; 29: 421-425
• 41 Thalib L, Gras L, Romand S. et al. Prediction of congenital toxoplasmosis by polymerase chain reaction analysis of amniotic fluid. BJOG Int J Obstet Gynaecol 2005; 112: 567-574
• 42 Prusa A-R, Kasper DC, Pollak A. et al. Amniocentesis for the detection of congenital toxoplasmosis: results from the nationwide Austrian prenatal screening program. Clin Microbiol Infect 2015; 21: 191.e1-191.e8
• 43 Salomon LJ, Sotiriadis A, Wulff CB. et al. Risk of miscarriage following amniocentesis or chorionic villus sampling: systematic review of literature and updated meta-analysis. Ultrasound Obstet Gynecol 2019; 54: 442-451
• 44 Patel DV, Holfels EM, Vogel NP. et al. Resolution of intracranial calcifications in infants with treated congenital toxoplasmosis. Radiology 1996; 199: 433-440
• 45 Blondiaux E, Garel C. Fetal cerebral imaging – ultrasound vs. MRI: an update. Acta Radiol 2013; 54: 1046-1054
• 46 Berrebi A, Bardou M, Bessieres M-H. et al. Outcome for children infected with congenital toxoplasmosis in the first trimester and with normal ultrasound findings: a study of 36 cases. Eur J Obstet Gynecol Reprod Biol 2007; 135: 53-57
• 47 Mandelbrot L, Kieffer F, Wallon M. et al. Toxoplasmose pendant la grossesse: proposition actuelle de prise en charge pratique. Gynecol Obstet Fertil Senol 2021; 49: 782-791
• 48 Di Mascio D, Rizzo G, Khalil A. et al. Role of fetal magnetic resonance imaging in fetuses with congenital cytomegalovirus infection: multicenter study. Ultrasound Obstet Gynecol 2023; 61: 67-73
• 49 Mandelbrot L, Kieffer F, Sitta R. et al. Prenatal therapy with pyrimethamine + sulfadiazine vs. spiramycin to reduce placental transmission of toxoplasmosis: a multicenter, randomized trial. Am J Obstet Gynecol 2018; 219: 386.e1-386.e9
• 50 Schoondermark-van de Ven EM, Melchers WJ, Galama JM. et al. Prenatal diagnosis and treatment of congenital Toxoplasma gondii infections: an experimental study in rhesus monkeys. Eur J Obstet Gynecol Reprod Biol 1997; 74: 183-188
• 51 Cortina-Borja M, Tan HK, Wallon M. et al. Prenatal Treatment for Serious Neurological Sequelae of Congenital Toxoplasmosis: An Observational Prospective Cohort Study. PLoS Med 2010; 7: 11
• 52 Gras L, Wallon M, Pollak A. et al. European Multicenter Study on Congenital Toxoplasmosis. Association between prenatal treatment and clinical manifestations of congenital toxoplasmosis in infancy: a cohort study in 13 European centres. Acta Paediatr 2005; 94: 1721-1731
• 53 Schuster S, Janatzek S, Chittka L. IGeLMonitor- Evidenz ausführlich – Toxoplasmose-Test in der Schwangerschaft. Accessed September 10, 2022 at: https://www.igel-monitor.de/fileadmin/user_upload/Toxoplasmosetest_Schwangerschaft_Evidenz_ausfuehrlich.pdf
• 54 Katlama C, De Wit S, OʼDoherty E. et al. Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis 1996; 22: 268-275
• 55 Araujo FG, Remington JS. Effect of Clindamycin on Acute and Chronic Toxoplasmosis in Mice. Antimicrob Agents Chemother 1974; 5: 647-651
• 56 Buonsenso D, Pata D, Turriziani Colonna A. et al. Spyramicine and Trimethoprim-Sulfamethoxazole Combination to Prevent Mother-To-Fetus Transmission of Toxoplasma gondii Infection in Pregnant Women: A 28-Years Single-center Experience. Pediatr Infect Dis J 2022; 41: e223-e227
• 57 EACSociety. EACS Guidelines. Accessed September 17, 2022 at: https://www.eacsociety.org/guidelines/eacs-guidelines/
• 58 Reiter-Owona I, Hlobil H, Enders M. et al. Sulfadiazine plasma concentrations in women with pregnancy-acquired compared to ocular toxoplasmosis under pyrimethamine and sulfadiazine therapy: a case-control study. Eur J Med Res 2020; 25: 59
• 59 Peytavin G, Leng JJ, Forestier F. et al. Placental transfer of pyrimethamine studied in an ex vivo placental perfusion model. Biol Neonate 2000; 78: 83-85
• 60 Wehbe K, Pencole L, Lhuaire M. et al. Hygiene measures as primary prevention of toxoplasmosis during pregnancy: A systematic review. J Gynecol Obstet Hum Reprod 2022; 51: 102300
• 61 Gemeinsamer Bundesausschuss. Mutterschafts-Richtlinien. 2021. Accessed April 18, 2023 at: https://www.g-ba.de/downloads/62-492-2676/Mu-RL_2021-09-16_iK-2022-01-01.pdf
• 62 Prusa A-R, Kasper DC, Sawers L. et al. Congenital toxoplasmosis in Austria: Prenatal screening for prevention is cost-saving. PLoS Negl Trop Dis 2017; 11: e0005648
• 63 SGGG. Expertenbrief 31 – Verzicht auf das Toxoplasmose-Screening in der Schwangerschaft – kurze zusammenfassende Begründung. 2010. Accessed September 17, 2022 at: https://www.sggg.ch/fileadmin/user_upload/PDF/31_Toxoplasmose-Screening_2010.pdf
• 64 Wallon M, Kieffer F, Huissoud C. et al. Cesarean delivery or induction of labor does not prevent vertical transmission of toxoplasmosis in late pregnancy. Int J Gynaecol Obstet 2015; 129: 176-177
• 65 Arbeitsgruppe Infektiologie der Österreichischen Gesellschaft für Kinderheilkunde. Österreichische Richtlinie für das Toxoplasmose-Screening in der Schwangerschaft und frühen Kindheit. 2013. Accessed January 21, 2021 at: https://www.oeghmp.at/media/richtlinie_toxoplasmose-screening.pdf
• 66 Wichtige humane Parasitosen: Toxoplasmose. Z Gastroenterol 2020; 58: 742-746